But until now drug companies had largely ignored Ebola, because there appeared to be little profit in developing a drug for populations that could not afford to pay for it.
Farmaceutické společnosti však dosud ebolu v podstatě ignorovaly, protože vývoj léku pro populace, které si ho nebudou moci dovolit, nesliboval velký zisk.